Agomelatine augmentation of sertraline in the treatment of moderate to severe obsessive-compulsive disorder: a randomized double-blinded placebo-controlled clinical trial
Abstract Background As 40–60% of the patients with obsessive-compulsive disorder (OCD) do not adequately respond to the first-line treatment, finding an effective second-line treatment is required. Our aim was to assess the efficacy and safety of agomelatine (a selective melatonin receptor agonist a...
محفوظ في:
| المؤلفون الرئيسيون: | , , , , , , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
BMC
2023-09-01
|
| سلاسل: | BMC Psychiatry |
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://doi.org/10.1186/s12888-023-05189-7 |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|